When comparing the hepatitis B vaccination with a cytosine phosphoguanine adjuvant (HepB-CpG) vaccination to the HepB-alum vaccine, the statistical threshold for a higher risk of acute myocardial infarction was not met, says an article published in the Journal of American Medical Association.
In prelicensure trials, a 2-dose HepB-CpG vaccine (Heplisav-B) produced greater seroprotection than a 3-dose hepatitis B vaccine with an aluminium hydroxide adjuvant (HepB-alum vaccine; Engerix-B). However, in one trial, those who received the HepB-CpG vaccine had a higher rate of acute myocardial infarction (MI) than those who received the HepB-alum vaccine, a finding that warrants additional investigation. Katia Bruxvoort and colleagues undertook this study to examine the rate of acute MI in recipients of the HepB-CpG and HepB-alum vaccines.
Kaiser Permanente Southern California (KPSC), an integrated health care system with 15 medical sites and nearly 4.7 million members, undertook this prospective cohort noninferiority trial. From August 7, 2018, to October 31, 2019, 69 625 people who were not on dialysis received at least one dose of hepatitis B vaccine in either the family medicine or internal medicine departments at KPSC (November 30, 2020, final follow-up). Receipt of HepB-CpG vaccine vs. HepB-alum vaccine were given to the subjects. The index dose was given initially during the trial period.
The main findings of this study were as follow:
1. 51.2% (n = 15 965) of the 31 183 HepB-CpG vaccine recipients were men, and 52.7% (n = 16 423) were Hispanic.
2. 50.8% (19 533) of the 38 442 HepB-alum recipients were men, and 47.1% (n = 18 125) were Hispanic.
3. After IPTW, the vaccine groups were well-balanced in terms of characteristics.
4. Fifty-two type 1 acute MI events were confirmed among HepB-CpG vaccination recipients, resulting in a rate of 1.67 per 1000 person-years, while 71 type 1 acute MI events were confirmed among HepB-alum vaccine recipients, resulting in a rate of 1.86 per 1000 person-years.
In conclusion, when comparing the HepB-CpG vaccination to the HepB-alum vaccine, the statistical threshold for an increased risk of acute myocardial infarction was not met.
Reference: Bruxvoort K, Slezak J, Qian L, et al. Association Between 2-Dose vs 3-Dose Hepatitis B Vaccine and Acute Myocardial Infarction. JAMA. Published online March 25, 2022. doi:10.1001/jama.2022.2540
Keywords: myocardial infarction, Hepatitis B, aluminium, vaccine, cytosine, phosphoguanine, cardiovascular, JAMA
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.